The Flagship Pioneering spinout uses permanent bonds to target shallow pockets, drastically expanding the druggable universe for small molecules.

A version of this story appeared in Volume 101, Issue 36 Not too long ago, these small-molecule drugs looked as if they were going out of fashion. Advances in biotechnology enabled pharmaceutical ...

Biomea Fusion is a clinical-stage company focused on developing covalent small molecules for diabetes and genetically-defined cancers. The company highlighted positive phase 2 trial results for its ...

Pearl Huang learned how important it is to choose the right drug modality for a target on the first project of her biopharma career. When she joined Merck & Co. as a biochemist in 1990, she was tasked ...